Immunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients.

We report the immunomodulatory effects of an intravenous treatment with F(ab')2 fragments of the bispecific monoclonal antibody BIS-1 during subcutaneous recombinant interleukin 2 (rIL-2) therapy of renal cell cancer (RCC) patients. BIS-1 is directed against both the CD3 antigen on T cells and...

Descripción completa

Detalles Bibliográficos
Autores principales: Janssen, R. A., Kroesen, B. J., Buter, J., Mesander, G., Sleijfer, D. T., The, T. H., Mulder, N. H., de Leij, L.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033869/
https://www.ncbi.nlm.nih.gov/pubmed/7669598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033869/
https://www.ncbi.nlm.nih.gov/pubmed/7669598

Ejemplares similares